Article

Editorial

Ann Lab Med 2024; 44(1): 1-2

Published online January 1, 2024 https://doi.org/10.3343/alm.2024.44.1.1

Copyright © Korean Society for Laboratory Medicine.

Challenges of Carbapenem-resistant Pseudomonas aeruginosa in Infection Control and Antibiotic Management

Young Jin Kim, M.D., Ph.D.1 , Hee Jae Huh, M.D., Ph.D.2 , and Heungsup Sung, M.D., Ph.D.3

1Department of Laboratory Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea; 2Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 3Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence to: Heungsup Sung, M.D., Ph.D.
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
E-mail: sung@amc.seoul.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infections caused by carbapenemase-producing gram-negative bacteria are recognized as a serious problem because of their high transmission and mortality rates [1]. To combat the transmission and spread of carbapenem-resistant bacteria, the Korean government and private sector have collaboratively established the Korea Global Antimicrobial Resistance Surveillance System (Kor-GLASS) in coordination with the WHO GLASS to monitor antimicrobial resistance in blood isolates from tertiary hospitals nationwide [2]. According to publicly available data from 2016 to 2021, Pseudomonas aeruginosa has shown a worrisome trend of increased resistance to imipenem (18.6% to 36.8%) and meropenem (14.7% to 35.1%) [3].

Carbapenemase-producing P. aeruginosa (CPPA) can cause various infections, with urinary tract infection (UTI) being a common healthcare-associated infection frequently caused by CPPA [4]. CPPA exhibits resistance to almost all antimicrobial agents, making treatment challenging. Colistin has been used to treat UTIs caused by CPPA; however, its use is restricted by severe side effects, such as nephrotoxicity and neurotoxicity, as well as the absence of standardized commercial susceptibility tests [5]. New-generation β-lactamase inhibitors have been approved in the United States and Europe; however, in Korea, the introduction of new treatments for multidrug-resistant gram-negative bacteria has been limited [5, 6]. Additionally, there is currently no commercially available new β-lactamase inhibitor effective against metallo-β-lactamase [7].

Amidst the concern caused by the recent emergence of New Delhi metallo-β-lactamase (NDM)-producing P. aeruginosa and Enterobacterales in Korea [8, 9], the increase in the frequency of NDM-producing CPPA isolates from patients with UTI reported by Jeong, et al. [10] in this issue of Annals of Laboratory Medicine is of great concern. This study sheds light on the increasing frequency of carbapenemase genotypes and identifies risk factors for CPPA UTIs, which are expected to aid in controlling CPPA in the future. The indiscriminate use of carbapenem-class antibiotics has been implicated in the spread of resistant bacteria in previous studies and has now been confirmed as an independent risk factor for UTI and mortality [10]. Although the introduction of new β-lactamase inhibitors in combination with β-lactam antibiotics has shown promise in addressing multidrug-resistant infections, it is important to note that the emergence of resistance has already been reported [11]. The results of Jeong, et al. [10] emphasize the need for antibiotic stewardship programs and careful selection of treatment options, particularly for patients exposed to carbapenems and presenting with increased white blood cell counts in the intensive care unit (ICU) setting. These findings can be helpful for ICU healthcare professionals, infection control practitioners, policymakers, and public health officials.

Alongside efforts and institutional support for the timely application of new drugs in the healthcare field, it is crucial to reduce unnecessary carbapenem use and expand antimicrobial stewardship and diagnostic stewardship programs to ensure the judicious use of antibiotics in the required spectrum [12, 13]. Continuous epidemiological monitoring studies, clinical trials for the development and introduction of new antibiotics, and research focused on the development of susceptibility testing methods for the early detection of resistance need to be consistently pursued.

Kim YJ, Huh HJ, and Sung H wrote and revised the manuscript. All authors reviewed and approved the manuscript.

  1. Hansen GT. Continuous evolution: perspective on the epidemiology of carbapenemase resistance among Enterobacterales and other gram-negative bacteria. Infect Dis Ther 2021;10:75-92.
    Pubmed KoreaMed CrossRef
  2. Liu C, Yoon EJ, Kim D, Shin JH, Shin JH, Shin KS, et al. Antimicrobial resistance in South Korea: a report from the Korean global antimicrobial resistance surveillance system (Kor-GLASS) for 2017. J Infect Chemother 2019;25:845-59.
    Pubmed CrossRef
  3. Korea Centers for Disease Control and Prevention. Kor-GLASS antimicrobial resistance rate. https://www.kdca.go.kr/nohas/en/statistics/selectARStatisticsMainTab.do?systemName=Kor_GLASS (Updated on Dec 2022).
  4. Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. Lancet Microbe 2023;4:e159-70.
    Pubmed CrossRef
  5. Lee HJ and Lee DG. Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria. Korean J Intern Med 2022;37:271-80.
    Pubmed KoreaMed CrossRef
  6. Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y, et al. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2022;60:106633.
    Pubmed CrossRef
  7. Mojica MF, Rossi MA, Vila AJ, Bonomo RA. The urgent need for metallo-beta-lactamase inhibitors: an unattended global threat. Lancet Infect Dis 2022;22:e28-34.
    Pubmed CrossRef
  8. Choi YJ, Kim YA, Junglim K, Jeong SH, Shin JH, Shin KS, et al. Emergence of NDM-1-producing Pseudomonas aeruginosa sequence type 773 clone: shift of carbapenemase molecular epidemiology and spread of 16S rRNA methylase genes in Korea. Ann Lab Med 2023;43:196-9.
    Pubmed KoreaMed CrossRef
  9. Jeong S, Lee N, Park MJ, Jeon K, Kim HS, Kim HS, et al. Genotypic distribution and antimicrobial susceptibilities of carbapenemase-producing Enterobacteriaceae isolated from rectal and clinical samples in Korean university hospitals between 2016 and 2019. Ann Lab Med 2022;42:36-46.
    Pubmed KoreaMed CrossRef
  10. Jeong S, Jeon K, Lee N, Park MJ, Song W. Changing genotypic distribution, antimicrobial susceptibilities, and risk factors of urinary tract infection caused by carbapenemase-producing Pseudomonas aeruginosa. Ann Lab Med 2024;44:38-46.
    Pubmed CrossRef
  11. Zhang P, Shi Q, Hu H, Hong B, Wu X, Du X, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect 2020;26:124.e1-4.
    Pubmed CrossRef
  12. Fatemi Y and Bergl PA. Diagnostic stewardship: appropriate testing and judicious treatments. Crit Care Clin 2022;38:69-87.
    Pubmed CrossRef
  13. Zakhour J, Haddad SF, Kerbage A, Wertheim H, Tattevin P, Voss A, et al. Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance. Int J Antimicrob Agents 2023;62:106816.
    Pubmed CrossRef